PAN-811 inhibits oxidative stress-induced cell death of human alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species

Journal of Alzheimer's Disease

Volumn 17, Issue 3, 2009, Pages 611-619

  Nelson, Valery M ^a   Dancik, Chanteé M ^a,b   Pan, Weiying ^a,c   Jiang, Zhi Gang ^a   Lebowitz, Michael S ^a   Ghanbari, Hossein A ^a  

^a Panacea Pharmaceuticals Inc   (United States)

^b GENEDX   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Neuroprotection; Olfactory neuroepithelium (ON); Oxidative stress; PAN 811

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; AMYLOID BETA PROTEIN; DNA; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; PAN 811; REACTIVE OXYGEN METABOLITE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CANCER THERAPY; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NERVE CELL; NEUROEPITHELIUM; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 67849119170     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1078     Document Type: Article

References (51)

1. Katzman R (1986) Alzheimer's disease. N EnglJ Med 314, 964-973.
2. Smith MA (1998) Alzheimer's disease. Int Rev Neurobiol 42, 1-54.
3. The World Health Report 2000 - health systems: improving performance, World Health Organization, http://www.who. int/whr/2000/en/, Accessed on January 8, 2009.
4. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
5. Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56, 321-339.
6. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
7. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248, 492-495.
8. Dowjat WK, Wisniewski H, Wisniewski T (2001) Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments. Neuroscience 103, 1-8.
9. Stoothoff WH, Johnson GV (2005) Tau phosphorylation: physiological and pathological consequences. Biochim BiophysActa 1739, 280-297.
10. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146.
11. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim BiophysActa 1502, 139-144.
12. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate,and neurodegenerative disorders. Science 262, 689-695.
13. de laTorre JC (2004) Alzheimer's disease is avasocognopathy:a new term to describe its nature. Neurol Res 26, 517-524.
14. Roman GC (2005) Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 20, 91-100.
15. Xu W, Chi L, Row BW, Xu R, Ke Y, Xu B, Luo C, Kheiran dish L, Gozal D, Liu R (2004) Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 126, 313-323.
16. Fearon IM, Brown ST, Hudasek K, Scragg JL, Boyle JP, Peers C (2006) Mitochondrial ROS production initiates Abeta1-40-mediated up-regulation of L-type Ca2+ channels during chronic hypoxia. Adv Exp Med Biol 580, 197-201.
17. Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA (2002) Reactive oxygen: its sources and significance in Alzheimer disease. JNeural Transm Suppl 62, 69-75.
18. Aliev G, Smith MA, de la Torre JC, Perry G (2004) Mitochondria as a primary target for vascular hypoperfusion and oxida- tive stress in Alzheimer's disease. Mitochondrion 4, 649-663.
19. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628.
20. Apelt J, Bigl M, Wunderlich P, Schliebs R (2004) Agingrelated increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimerlike pathology. Int J Dev Neurosci 22, 475-484.
21. Doty RL, Perl DP, Steele JC, Chen KM, Pierce JD Jr, Reyes P, Kurland LT (1991) Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 46, 47-51.
22. Kovacs T, Cairns NJ, Lantos PL (2001) Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. Neuroreport 12, 285-288.
23. Strous RD, Shoenfeld Y (2006) To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 6, 54-60.
24. Attems J, Jellinger KA (2006) Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 25, 265-271.
25. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H (2008) Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 29, 693-706.
26. Kovacs T, Cairns NJ, Lantos PL (1999) Beta-amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease. Neuropathol Appl Neuro- biol 25, 481-491.
27. Wolozin B, Bacic M, Merrill MJ, Lesch KP, Chen C, Lebovics RS, Sunderland T (1992) Differential expression of carboxyl terminal derivatives of amyloid precursor protein among cell lines. JNeurosci Res 33, 163-169.
28. Wolozin B, Sunderland T, Zheng BB, Resau J, Dufy B, Barker J, Swerdlow R, Coon H (1992) Continuous culture ofneuronal cells from adult human olfactory epithelium. J Mol Neurosci 3, 137-146.
29. Wolozin B, Lesch P, Lebovics R, Sunderland T, Bennett AE (1993) Olfactory neuroblasts from Alzheimer donors: studies on APP processing and cell regulation. Biol Psychiatry 34,824-838.
30. Johnson GS, Basaric-Keys J, Ghanbari HA, Lebovics RS, Lesch KP, Merril CR, Sunderland T, Wolozin B (1994) Protein alterations in olfactory neuroblasts from Alzheimer donors. Neurobiol Aging 15, 675-680.
31. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghan- bari K, Jones PK, Cordone G, Tabaton M, Wolozin B, Ghan- bari H (2003) Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol (Berl) 106, 552-556.
32. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, Wolozin BL, Smith MA, Perry G (2004) Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 3, 41-44.
33. Jiang ZG, Lu XC, Nelson V, Yang X, Pan W, Chen RW, Lebowitz MS, Almassian B, Tortella FC, Brady RO, Ghanbari HA (2006) A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia. Proc Natl Acad Sci USA 103,1581-1586.
34. Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29,222-230.
35. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology ofageing. Nature 408, 239-247.
36. Behl C, Moosmann B (2002) Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotec- tive compounds. Biol Chem 383, 521-536.
37. Lynch T, Cherny RA, Bush AI (2000) Oxidative processes in Alzheimer's disease: the role ofabeta-metal interactions. Exp Gerontol 35, 445-451.
38. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283, 1482-1488.
39. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, Smith MA (2002)Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70, 357-360.
40. Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM (2003) Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 5, 209-228.
41. Kamalvand G, Ali-Khan Z (2004) Immunolocalization oflipid peroxidation/advanced glycation end products in amyloid A amyloidosis. Free Radic Biol Med 36, 657-664.
42. Catala A (2006) An overview of lipid peroxidation with emphasis in outer segments of photoreceptors and the chemiluminescence assay. Int J Biochem Cell Biol 38, 1482-1495.
43. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP (1997) Impairment of glucose and gluta- mate transport and induction ofmitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal. Neurochem 69, 273-284.
44. Bruce-Keller AJ, Lt YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP (1998) Hydrox- ynonenal a product of lipid peroxidation, damages choliner- gic neurons and impairs visuospatial memory in rats. Neuropathol Exo Neurol 57, 257-267.
45. Kruman I, Bruce-Keler AJ, Bredesen D, Weag G, Mattson MP (1997) Evidence that 4-hydroxynonenyl mediates oxidative stress-induced neuronal apoptosis. J Neurosci 17, 5089-5100.
46. Cenini G, Sultana R, Memo M, Butterfield DA (2008) Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J Cell Mol Med 12, 987-994.
47. Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR (2005) Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 4, 383-403.
48. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K,Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. NEngl JMed 336, 1216-1222.
49. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G (2001) Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32, 275-282.
50. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278, 1327-1332.
51. Liu MC, Lin TS, Sartorelli AC (1992) Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 35, 3672-3677.